Cedilla Therapeutics

Bayer is still in the midst of a radical overhaul of its business but has returned to in-licensing oncology assets via a deal with NextRNA Therapeutics and its novel small molecule platform. Findin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Antibiotics Firm Agrees To Go Private F

The biotechnology company creator and funder Flagship Pioneering and the Cystic Fibrosis Foundation announced a strategic partnership on 3 November under which the CF Foundation has committed up to

Venture capital fundraising by biopharmaceutical companies in 2020 totaled $19.5bn during the first three quarters of 2020, which beats the full year 2019 total of $17.4bn and is on track to surpass t